COMPASS Pathways plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that COMPASS Pathways plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($287.86M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($155.12M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($118.46M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($91.51M) | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | ($71.74M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($60.33M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($19.61M) | Feb 24, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($179.04M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($178.21M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($136.92M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($110.40M) | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | ($83.22M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($51.39M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($21.18M) | Feb 24, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.44M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $119.04M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $87.52M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $65.05M | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | $44.03M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $23.37M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $12.56M | Feb 24, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($157.24M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($119.19M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($97.38M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($105.45M) | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | ($67.75M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($41.38M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($17.81M) | Feb 24, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $66.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $596.0K | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | $334.0K | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $131.0K | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $165.0K | Feb 24, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $210.35M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $213.67M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $275.99M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $197.29M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $300.90M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $203.46M | Feb 24, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $263.20M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $58.97M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $50.24M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $16.01M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $16.49M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $6.90M | Feb 24, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.85M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $154.70M | Mar 24, 2026 |
| FY2025 | Dec 31, 2023 | $225.74M | Mar 24, 2026 |
| FY2024 | Dec 31, 2022 | $181.28M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $284.41M | Feb 29, 2024 |
| FY2023 | Dec 31, 2020 | $196.56M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | ($30.39M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | ($14.37M) | Feb 24, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($822.59M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($534.73M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($379.61M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($261.15M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($169.64M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($97.90M) | Feb 24, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $149.61M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $165.08M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $220.20M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $143.21M | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | $273.24M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $190.33M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $24.97M | Feb 24, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.63M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $30.17M | Mar 24, 2026 |
| FY2023 | Dec 31, 2023 | $28.76M | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $0 | Feb 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 96.09M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 68.55M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 61.94M | Feb 27, 2025 |